Orgenesis (NASDAQ:ORGS) Shares Down 2.6%

Orgenesis Inc. (NASDAQ:ORGS)’s share price fell 2.6% during trading on Friday . The company traded as low as $0.65 and last traded at $0.69. 84,189 shares were traded during mid-day trading, an increase of 22% from the average session volume of 69,132 shares. The stock had previously closed at $0.71.

Orgenesis Price Performance

The business has a 50-day moving average price of $0.90 and a two-hundred day moving average price of $1.12. The company has a quick ratio of 0.73, a current ratio of 0.73 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $19.64 million, a price-to-earnings ratio of -1.60 and a beta of 1.07.

Orgenesis (NASDAQ:ORGS) last released its quarterly earnings data on Friday, August 11th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.21). The business had revenue of $6.98 million for the quarter. Orgenesis had a negative return on equity of 40.31% and a negative net margin of 31.76%.

Institutional Trading of Orgenesis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its position in shares of Orgenesis by 7.5% during the first quarter. State Street Corp now owns 88,659 shares of the company’s stock valued at $308,000 after buying an additional 6,159 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Orgenesis by 3.6% during the 4th quarter. Geode Capital Management LLC now owns 206,754 shares of the company’s stock worth $403,000 after acquiring an additional 7,198 shares during the last quarter. BlackRock Inc. grew its stake in shares of Orgenesis by 8.6% in the 2nd quarter. BlackRock Inc. now owns 132,572 shares of the company’s stock worth $184,000 after acquiring an additional 10,541 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Orgenesis by 49.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,409 shares of the company’s stock valued at $71,000 after purchasing an additional 12,000 shares during the last quarter. Finally, Walleye Capital LLC bought a new position in shares of Orgenesis during the second quarter valued at about $99,000. 9.93% of the stock is owned by institutional investors.

Orgenesis Company Profile

Orgenesis Inc, a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network.